The Scientist - USA (2020-01 & 2020-02)

Biomolecule purifi cation involves a complex series of steps in which target purity and recovery are vital. Many common nucleic acid and protein

handling procedures can benefi t from the use of centrifugal devices outfi tted with microfi ltration or ultrafi ltration membranes. But fi nding the right

products can be challenging. This webinar, sponsored by Pall Laboratory, highlights ways to simplify purifi cation in the molecular biology lab.

JORGEN DE HAAN,PhD

Senior Application Scientist

Pall Laboratory

ORIGINALLY AIRED

THURSDAY, NOVEMBER 21, 2019

WATC H NOW!

http://www.the-scientist.com/centrifugal_devices_pall

TOPICS COVERED:

• The interplay between membrane selection, sample composition, and
  centrifugation conditions


• Device choices available for processing nucleic acid and protein samples
  ranging in volume from 50 μL to 60 mL


• Nucleic acid applications


• Cleanup of DNA fragments, such as PCR products, prior to restriction,
  digestion, and labeling reactions


• Gel purification of DNA fragments


• Protein applications


• Concentration, fractionation, and desalting or buffer exchange (diafiltration)


• Elution of proteins from polyacrylamide gels

WEBINAR SPONSORED BY

ONDEMAND

ONDEMAND

How Centrifugal Devices Facilitate Molecular

Biology Research

Simplifying Patient Participation in Research Studies

Research depends on samples from patients and healthy volunteers. But obtaining biospecimens from human subjects can be a challenge for

researchers and patients alike. Home-based specimen collection directly connects patients to researchers, while alleviating the burden of travel

to secondary sites. Using this approach, researchers effi ciently collect patient samples in the comfort of their homes. This webinar, sponsored by

Sanguine, details research experiences from researcher and patient perspectives.

CHRISTINE VON RAESFELD

Independent Patient Advocate

Board member, More Than Lupus

Patient Advisor, Aurinia Pharmaceuticals

Patient Advisor, PatientsLikeMe

Participant in the Stanford Humanwide Program

ORIGINALLY AIRED

TUESDAY, DECEMBER 10, 2019

WATC H NOW!

http://www.the-scientist.com/simplifying-patient-participation

STEPHANIE CULLER,PhD

Co-Founder and CEO

Persephone Biome, Inc.

TOPICS COVERED:

• Development of an AI drug discovery platform for
  microbial-based immunotherapies using patient samples


• Research from a patient’s perspective


• Practical considerations for engaging patients in research


• The direct-to-patient trial model

WEBINAR SPONSORED BY